InvestorsHub Logo
Followers 38
Posts 1638
Boards Moderated 0
Alias Born 01/23/2014

Re: None

Friday, 08/21/2015 8:19:55 AM

Friday, August 21, 2015 8:19:55 AM

Post# of 2804248
$AVEO - POSITIVE RESULTS FROM THE PRE-CLINICAL DATA

Results demonstrated that the inhibition of GDF15 function results in the complete reversion of the phenotypic and metabolic changes associated with cancer-related anorexia-cachexia syndrome, or CACS, completely reverting body weight loss and restoring normal body composition of the tumor bearing mice. AV-380 treatment resulted in a catabolic to anabolic metabolic switch and increased food intake, energy expenditure, resting energy expenditure and physical activity. The data highlight the potential of AV-380 as a therapeutic intervention for the treatment for CACS.

http://www.reuters.com/article/2015/04/20/ma-aveo-oncology-idUSnBw205124a+100+BSW20150420
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.